FDA’s final reference document on expedited regulatory pathways clarifies several aspects of the “breakthrough therapy” program, including the types of “preliminary clinical evidence” that would support a designation.
The guidance, “Expedited Programs for Serious Conditions – Drug and Biologics,” defines what the agency means by preliminary clinical evidence under the breakthrough program and includes examples of...